AI주식인사이트AI Stock Insight
C

인투셀

287840KOSDAQ

41.5 / 100

Reference Date: 2026-09-08

Financial Score9.0 / 40
News Sentiment18.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Slightly down 3.6% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

IntuCell is an ADC platform technology company specializing in linker and drug development, leveraging its OHPAS linker and PMT platform technologies to enhance drug delivery efficiency and selectivity. The company utilizes proprietary drug technologies such as Duocarmycin and Nexatecan to establish a competitive edge in oncology, with a pipeline including the B7-H3-targeting ADC candidate ITC-6146RO.

Number of Employees

—

Average Salary

—

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 15.004.0Point
PBR
10.53Industry Average 1.200.0Point

8.8x industry avg (risky)

ROE
-65.72Industry Average 8.000.0Point

Well below industry avg

Debt Ratio
53.66Industry Average 100.005.0Point

Lower than industry avg (good)

Trend 2024~20250.0 / 10 points
Revenue Growth Rate
0.0 / 3

Avg ▼20.9% (1-year basis)

Operating Profit Growth Rate
0.0 / 3

Avg ▼5.2% (1-year basis)

ROE Trend
0.0 / 4

Avg ROE -80.6% (improving, 2yr)

Detailed News Sentiment

5 totalPositive 4Neutral 1Negative 0Average Sentiment Score 74

Detailed Momentum

52-week position1.0Point

Near 52w low (6%, downtrend)

Current 17,350Won52-week high 71,00052-week low 13,850
1-month return2.0Point

1m -3.61% (slight drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral기업설명회(IR)개최2026-08-18
  • Neutral반기보고서 (2026.06)2026-08-14